Type 2 Diabetes

Latest News

Preterm Birth May Increase Risk for Type 1 and Type 2 Diabetes

By

Amit Akirov, MD

The risk for type 1 and type 2 diabetes from childhood into adulthood is increased in preterm-born individuals.

Low BMD Linked to SHBG Levels in Postmenopausal Women With T2D

By

Hannah Dellabella

Women with higher serum SHBG had an increased risk for osteoporosis, osteopenia, and fracture.

CPAP Compliance in OSA and Type 2 Diabetes Lowers Risk for Diabetic Retinopathy

By

Sheila Jacobs

Increased compliance with continuous positive airway pressure therapy may reduce the risk for the development of diabetic retinopathy in patients with type 2 diabetes who have obstructive sleep apnea.

Systolic Blood Pressure, LDL Linked to Peripheral Neuropathy Risk in Type 2 Diabetes

By

Laurell Haapanen

Higher systolic blood pressure and decreased low-density lipoprotein are associated with increased risk for peripheral neuropathy in patients with type 2 diabetes.

SGLT2 Inhibitors Linked to Less Renal Deterioration Across All CKD Stages

By

Amit Akirov, MD

Treatment with SGLT2 inhibitors empagliflozin and dapagliflozin may be associated with less decline in kidney function across different chronic kidney disease stages.

HbA1c Variability Linked to Cardiovascular Disease Risk

For patients with newly diagnosed type 2 diabetes, visit-to-visit HbA1c variability is associated with increased risks for cardiovascular disease and microvascular complications.

Variability in Sleep Duration May Affect Blood Glucose Control in Diabetes

By

Laurell Haapanen

Sleep may be an important modifiable factor in disease management in patients with type 2 diabetes, especially variation in sleep duration.

Comparison of Canagliflozin and GLP-1 Receptor Agonists in Type 2 Diabetes

By

Amit Akirov, MD

Treatment with canagliflozin was associated with similar reductions in HbA1c compared with any dose of a GLP-1 receptor agonist, with better treatment adherence and lower annual costs.

Reduced Risk for HF Hospitalization With Empagliflozin vs Other Antidiabetic Agents

By

Diana Ernst, RPh

Treatment with empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was associated with reduced risk of hospitalization for heart failure when compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide (GLP)-1 receptor agonists.

Men With T2D, Osteoarthritis Experience More Severe Joint Pain With Insulin Use

By

Rose Reeb

A hospital-based cohort study found sex heterogeneity in the severity of osteoarthritis symptoms in type 2 diabetes, and an association between insulin treatment and pain severity in men.

Clinical Charts

Insulins

Insulin Pen Devices

Insulin Administration